Contents

Intravitreal Aflibercept for Diabetic Macular Edema (VISTA AND VIVID)

November 1, 2016

Clinical trial

Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.

Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, Boyer DS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Vitti R, Berliner AJ, Zeitz O, Metzig C, Holz FG.

Ophthalmology. 2016 Nov;123(11):2376-2385
Full text | Metrics.

Main finding: Intravitreal Alifbercept was superior to laser through 148 weeks, with similar efficacy in the 2q4 and 2q8 dosing groups.

 

  • Purpose: To compare efficacy and safety of 2 dosing regimens of intravitreal aflibercept injection with macular laser photocoagulation for diabetic macular edema
  • Study type: Randomized controlled trial
  • Condition: Diabetic Macular Edema

Participants: Type 1 or 2 DM, DME, BCVA 20/40–20/320

 

  • n=872

 

Intervention:

 

Groups:

 

Group 1: Aflibercept 2mg every 4 weeks (2q4)
Group 2: Aflibercept 2mg every 8weeks (2q8)
Group 3: Laser (macular)

Visual acuity improvements observed with both IAI regimens (over laser control) at weeks 52 and 100 were maintained at week 148.

Outcomes Group Aflibercept 2q4 Aflibercept 2q8 Laser
Mean BCVA gain VISTA +10.4 +10.5 +1.4
VIVID +10.3 +11.7 +1.6
Gain ≥ 15 letters from baseline (Proportion of patients) VISTA 42.9% 35.8% 13.6%
VIVID 41.2% 42.2% 18.9%

October 1, 2015

Clinical trial

Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.

Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Korobelnik JF.

Ophthalmology. 2015 Oct;122(10):2044-52.
Full text | Metrics.

Main finding: The 52-week visual and anatomic superiority of intravitreal Aflibercept over laser control was sustained through week 100, with similar efficacy in the 4-weekly and 8-weekly groups.

 

  • Purpose: To compare efficacy and safety of 2 dosing regimens of intravitreal aflibercept injection with macular laser photocoagulation for diabetic macular edema
  • Study type: Randomized controlled trial
  • Condition: Diabetic Macular Edema

Participants: Type 1 or 2 DM, DME, BCVA 20/40–20/320

 

  • n=872

 

Intervention:

 

Groups:

 

Group 1: Aflibercept 2mg every 4 weeks (2q4)
Group 2: Aflibercept 2mg every 8weeks (2q8)
Group 3: Laser (macular)

Visual acuity improvements observed with both IAI regimens (over laser control) at weeks 52 and 100 were maintained at week 148.

Outcomes Group Aflibercept 2q4 Aflibercept 2q8 Laser
Mean BCVA gain VISTA +10.4 +10.5 +1.4
VIVID +10.3 +11.7 +1.6
Gain ≥ 15 letters from baseline (Proportion of patients) VISTA 42.9% 35.8% 13.6%
VIVID 41.2% 42.2% 18.9%

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2024 - sourceshed